MRK - Cullinan gains as early trial for cancer drug indicates complete remission
2023-05-26 12:36:09 ET
Cullinan Oncology ( NASDAQ: CGEM ) rose ~8% on Friday after the biotech announced Phase 1 data for its solid tumor candidate CLN-619 indicating a complete remission and a favorable safety profile in a late-line setting.
In addition to one complete response seen in a patient with parotid gland cancer, there were two unconfirmed partial responses in patients with endometrial cancer, the company said.
The ongoing trial is designed to evaluate CLN-619 as monotherapy and in combination with Merck’s ( MRK ) anti-PD1 therapy Keytruda (pembrolizumab) in patients with advanced solid tumors.
The Cambridge, Massachusetts-based biotech shared monotherapy data from the study ahead of a presentation at next month’s American Society of Clinical Oncology (ASCO) Annual Meeting.
The patients had undergone a median of three prior systemic therapies, and 54% had received immune checkpoint inhibitor therapy.
In terms of safety, there were no dose-limiting toxicities across a range of CLN-619 doses, the company said, adding that it plans to begin monotherapy expansion cohorts in endometrial and cervical cancer.
More on Cullinan Oncology
- Cullinan Oncology wins FDA nod to run studies for another cancer therapy
- Cullinan: Trading Way Below Cash
For further details see:
Cullinan gains as early trial for cancer drug indicates complete remission